SEARCH

SEARCH BY CITATION

References

  • 1
    Howden CW & Hunt RH. The relationship between suppression of acidity and gastric ulcer healing rates. Aliment Pharmacol Ther 1990; 4: 25 33.
  • 2
    Howden CW, Burget DW, Hunt RH. A meta–analysis to predict gastric ulcer healing from acid suppression. Gastroenterology 1991; 100: A85.
  • 3
    Burget DE, Chiverton SG, Hunt RH. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology 1990; 99: 345 51.
  • 4
    Bell NJV, Burget DW, Wilkinson J, Hunt RH. Gastroesophageal reflux disease and gastric acid suppression: A meta–analysis to predict healing. Gastroenterology 1992; 102: A40.
  • 5
    Vaezi MF & Richter JE. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. Gastroenterology 1996; 111: 1192 9.
  • 6
    Bell NJV, Burget DW, Howden CW, et al. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992; 51(Suppl.): 59 67.
  • 7
    Unge P. Review of Helicobacter pylori eradication regimens. Scand J Gastroenterol 1996; 31(Suppl.) 215: 74 81.
  • 8
    Schwartz H, Krause R, Sahba B. Triple vs. dual therapy with lansoprazole (L), clarithromycin (C) and/or amoxicillin (A) in the eradication of Helicobacter pylori. Gastroenterology 1996; 91(9): 2047.
  • 9
    Muller P, Dammann HG, Leucht U, Dimon B. Human gastric acid secretion following repeated doses of AG-1749. Aliment Pharmacol Ther 1989; 3: 193 8.
  • 10
    Sanders SW, Tolman KG, Greski PA, et al. The effects of lansoprazole, a new H+,K+-ATPase inhibitor, on gastric pH and serum gastrin . Aliment Pharmacol Ther 1992; 6: 359 72.
  • 11
    Timmer W, Ripke H, Kleist P, et al. Effect of four lansoprazole dose levels and one dosage regimen of omeprazole on 24-h intragastric pH in healthy volunteers. Methods Find Exp Clin Pharmacol 1995; 17(7): 489–95.
  • 12
    Reill L & Erhardt F, Heinzerling, et al. Dose–response of pantoprazole 20, 40, and 80 mg on 24–h intragastric pH, serum pantoprazole and serum gastrin in man . Gastroenterology 1994; 106: A165.
  • 13
    Koop H, Kuly S, Flüg M, et al. Interactions of intragastric pH ans serum gastrin during administration of different doses of the new proton pump inhibitor pantoprazole. Dig Dis Sci 1994; 39: A1780.
  • 14
    Scholtz HE, Meyer BH, Luus R, et al. Comparison of the effects of lansoprazole, omeprazole, and pantoprazole on 24-h gastric pH in healthy males. S Afr Med J 1995; 8: A915.
  • 15
    McNulty CAM. Bacteriological and pharmacological basis for the treatment of Campylobacter pylori in gastric mucosa. Gastroenterol Clin Biol 1989; 13: 96B 100B.
  • 16
    Malanoski GJ, Eliopoulos GM, Ferraro MJ, et al. Effect of pH variation on the susceptibility of Helicobacter pylori to three macrolide antimicrobial agents and temafloxacin. Eur J Clin Microbiol Infect Dis 1993; 12: 131 3.
  • 17
    Westblom TU & Duriex DE. Enhancement of antibiotic concentrations in gastric mucosa by H2-receptor antagonist: implications for treatment of Helicobacter pylori infections. Dig Dis Sci 1991; 36: 25 8.